首页> 外文期刊>EFSA Journal >Scientific Opinion on the substantiation of health claims related to foods with reduced amounts of saturated fatty acids (SFAs) and maintenance of normal blood LDL cholesterol concentrations (ID 620, 671, 4332) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
【24h】

Scientific Opinion on the substantiation of health claims related to foods with reduced amounts of saturated fatty acids (SFAs) and maintenance of normal blood LDL cholesterol concentrations (ID 620, 671, 4332) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

机译:根据法规(EC)第13(1)条,关于减少饱和脂肪酸(SFA)含量的食品和维持正常血液LDL胆固醇浓度(ID 620、671、4332)的健康主张的科学意见1924/2006

获取原文
获取外文期刊封面目录资料

摘要

This opinion addresses the scientific substantiation of health claims in relation to foods with reduced amounts of saturated fatty acids and maintenance of normal blood LDL-cholesterol concentrations. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituents that are the subject of the health claim are “saturated fats/saturated fatty acids (decrease)” and “decrease of saturated fatty acids”. This opinion applies to mixtures of saturated fatty acids as present in foods. The Panel considers that saturated fatty acids (SFAs) are sufficiently characterised. The claimed effects are “blood cholesterol and artery/heart health”, and “cardio-vascular system”. The target population is assumed to be the general population. In the context of the proposed wordings and clarifications provided by Member States, the Panel assumes that the claimed effects refer to the maintenance of normal blood LDL-cholesterol concentrations. The Panel considers that maintenance of normal blood LDL-cholesterol concentrations is a beneficial physiological effect. The evidence provided by consensus opinions/reports from authoritative bodies and reviews shows that there is good consensus that a mixture of SFAs increases blood total and LDL-cholesterol concentrations relative to carbohydrates, which are considered neutral regarding their effects on 1 On request from the European Commission, Question No EFSA-Q-2008-1407, EFSA-Q-2008-1458, EFSA-Q-2010-00285, adopted on 28 January 2011. Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus L?vik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuh?user-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.
机译:该意见涉及与减少饱和脂肪酸含量并维持正常血液LDL-胆固醇浓度的食品有关的健康主张的科学依据。科学依据是成员国在第13条健康声明综合清单中提供的信息,以及EFSA从成员国或直接从利益相关者那里获得的参考。健康声明的主题食品成分是“饱和脂肪/饱和脂肪酸(减少)”和“饱和脂肪酸减少”。该意见适用于食品中存在的饱和脂肪酸混合物。小组认为,饱和脂肪酸具有足够的特征。声称的作用是“血液胆固醇和动脉/心脏健康”和“心血管系统”。假定目标人群为普通人群。在会员国提出的拟议措词和澄清的范围内,小组认为所要求的作用是指维持正常血液中LDL-胆固醇的浓度。专家组认为,维持血液中低密度脂蛋白胆固醇的正常浓度是有益的生理作用。权威机构和评论机构的共识性意见/报告提供的证据表明,人们普遍认为,SFA的混合物相对于碳水化合物会增加血液总量和LDL-胆固醇的浓度,就其对碳水化合物的影响而言,它们被认为是中性的。1欧盟委员会,问题编号EFSA-Q-2008-1407,EFSA-Q-2008-1458,EFSA-Q-2010-00285,于2011年1月28日通过。小组成员:卡洛·阿戈斯托尼,让·路易·布雷森,苏珊·费尔韦瑟·泰特,阿尔伯特·弗林(Albert Flynn),伊内斯·戈利(Ines Golly),汉努·科洪宁(Hannu Korhonen),帕戈纳·拉吉欧(Pagona Lagiou),马蒂努斯·拉维克(Martinus L?vik),罗桑杰拉·马尔凯利(Rosangela Marchelli),安布罗伊斯·马丁(Bebro Moseley),莫妮卡·诺伊(Neika Neuh)用户-贝特霍尔德(Herdegard Przyrembel),塞波·萨尔米宁(Seppo Salminen),尤兰达·桑兹(Yolandaard Sanz),肖恩(JJ)斯特林,斯蒂芬·斯特罗贝尔(Stephan Strobel) ,Inge Tetens,DanielTomé,Hendrik van Loveren和Hans Verhagen。

著录项

  • 来源
    《EFSA Journal》 |2011年第4期|共14页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种
  • 中图分类 食品工业;
  • 关键词

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号